NCT04611750已完成2 期
Pharmacological Intervention for Symptomatic Mild Sleep Disordered Breathing
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 53
- 试验地点
- 2
- 主要终点
- Snoring Relationship Questionnaire (SRQ)
研究概览
简要总结
Currently, there is no pharmacological intervention for mild symptomatic obstructive sleep disordered breathing (SDB) in the form of loud habitual snoring, inspiratory flow limitation (i.e. upper airway resistance syndrome), or mild sleep apnea. Here the investigators study the effect on SDB of stimulating pharyngeal muscles during sleep with AD036. The key hypothesis of the study is that AD036 is superior to placebo on self-reported and objective measures of SDB severity.
详细描述
This is a randomized placebo-controlled 2-period crossover study. Each crossover period will consist of 14 days of QHS dosing of either AD036 or placebo, with a washout period of 7 days between each period.
Polysomnography will be performed at screening (baseline) and on the last dosing day of each of the two crossover dosing period.
The trial will enroll participants until a total of 24 responders are randomized into the crossover portion of the study.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 25 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- 未提供
排除标准
- •Participants are excluded from the study if any of the following criteria apply:
- •History of narcolepsy
- •Clinically significant craniofacial malformation
- •Clinically significant cardiac disease (e.g., rhythm disturbances, coronary artery disease or cardiac failure) or hypertension requiring more than 2 medications for control.
- •Clinically significant neurological disorder, including epilepsy/convulsions.
- •History of schizophrenia, schizoaffective disorder or bipolar disorder
- •History of attempted suicide or suicidal ideation within 1 year prior to screening, or current suicidal ideation.
- •History of clinically significant constipation, gastric retention, or urinary retention.
- •Positive screen for drugs of abuse or substance use disorder
- •A significant illness or infection requiring medical treatment in the past 30 days.
- •Clinically significant cognitive dysfunction.
- •Untreated narrow angle glaucoma.
- •Women who are pregnant or nursing.
- •History of using oral or nasal devices for the treatment of OSA or snoring; may enroll as long as the devices are not used during participation in the study.
- •History of using devices to affect participant sleeping position for the treatment of OSA or snoring, e.g. to discourage supine sleeping position; may enroll as long as the devices are not used during participation in the study.
- •History of oxygen therapy (last 12 months).
- •Use of medications from the list of disallowed concomitant medications during study participation.
- •MAOIs or other drugs that affect monoamine concentrations (e.g., rasagiline) [MAOIs are contraindicated for use with atomoxetine]
- •Selective Serotonin Reuptake Inhibitors (e.g., paroxetine)
- •Selective Norepinephrine Reuptake Inhibitors (e.g., duloxetine)
- •Norepinephrine Reuptake Inhibitors (e.g., reboxetine)
- •Alpha-1 antagonists (e.g., tamsulosin)
- •Tricyclic antidepressants (e.g., desipramine)
- •Centrally acting antihypertensives (e.g. clonidine, alpha-methyl-DOPA)
- •CYP2D6 inhibitors
- •Strong CYP3A4 inhibitors (e.g., ketoconazole)
- •Benzodiazepines and other anxiolytics or sedatives
- •Nonbenzodiazepine hypnotics
- •Muscle relaxants
- •Pressor agents
- •Drugs with clinically significant cardiac QT-interval prolonging effects
- •Drugs known to lower seizure threshold (e.g., chloroquine)
- •Amphetamines
- •Antiepileptics
- •Antiemetics
- •Modafinil or armodafinil
- •Beta2 agonists, (e.g., albuterol)
- •Antipsychotics
- •Anticholinergics and anticholinesterase inhibitors, including drugs with substantial anticholinergic side effects, (e.g., first generation antihistamines)
- •Sedating antihistamines
- •Pseudoephedrine, phenylephrine, oxymetazoline
- •Nicotine replacement products
- •Most drugs for Parkinson's, Alzheimer's, Huntington's, Amyotrophic Lateral Sclerosis, or drugs for other neurodegenerative diseases
- •Treatment with strong cytochrome P450 3A4 (CYP3A4) inhibitors, strong cytochrome P450 2D6 (CYP2D6) inhibitors, or monoamine oxidase inhibitors (MAOI) within 14 days of the start of treatment, or concomitant with treatment.
- •Use of another investigational agent within 30 days or 5 half-lives prior to dosing, whichever is longer.
- •<5 hours typical sleep duration.
- •Smoking more than 10 cigarettes or 2 cigars per day.
- •Unwilling to use specified contraception.
- •Unwilling to limit alcohol consumption to no greater than 2 units/day or less for men, or 1 unit/day for women, not to be consumed within 3 hours of bedtime.
- •Unwilling to limit caffeinated beverage intake (e.g., coffee, cola, tea) to 400 mg/day or less of caffeine (approximately 4 cups of coffee); caffeine not to be used within 3 hours of bedtime.
- 另有 2 项未显示
研究组 & 干预措施
Active Medication (AD036)
Experimental
Participants will take AD036 QHS for 14 days.
干预措施: AD036 (Drug)
Placebo Medication
Placebo Comparator
Participants will take placebo QHS for 14 days.
干预措施: Placebo (Drug)
结局指标
主要结局
Snoring Relationship Questionnaire (SRQ)
时间窗: 14 days
Self-reported impact of snoring on relationship and quality of life for patients and bedpartners, 0-20 scale, 0 lowest severity, 20 highest severity
次要结局
- Flow Limitation Frequency(14 days)
- Snoring Frequency(14 days)
- Apnea-Hypopnea Index(14 days)
研究者
Scott Aaron Sands
Assistant Professor of Medicine
Brigham and Women's Hospital
研究点 (2)
Loading locations...
相似试验
已完成
1 期
Pharmacological Intervention for Symptomatic SnoringSnoringNCT03720353Brigham and Women's Hospital27
已完成
不适用
Suvorexant for the treatment of insomnia in patients with psychiatric disorderspsychiatric disordersJPRN-UMIN000024941Fujita Health University School of Medicine50
已完成
1 期
Combination Pharmacological Interventions for Multiple Mechanisms of Obstructive Sleep ApneaSleep ApneaNCT03892772Brigham and Women's Hospital23
进行中（未招募）
1 期
Treatment of sleep disturbance (insomnia) in patients with advanced cancer who use pain killers (opioids).The overall aim of this clinical trial is to improve the knowledge of the pharmacological treatment of insomnia in patients with advanced cancer who use opioids. Despite the high prevalence of insomnia in patients in advanced cancer, there are no randomized controlled data involving pharmacological interventions for insomnia in advanced cancer. Thus, there is a need to evaluate the effectiveness of zopiclone for insomnia patients with advanced cancer.EUCTR2015-005306-11-NOSt. Olavs Hospital, trondheim University Hospital100
招募中
1 期
Pharmacologically Targeting Sleep Spindles to Improve Cognition in AgeingACTRN12619001728123Woolcock Institute of Medical Research24